Royalty Pharma plc
RPRX
$31.79
$0.511.63%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -57.88% | 654.34% | -55.19% | -98.60% | 208.39% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 9.61% | 6.73% | -14.35% | -18.31% | -9.17% |
| Total Other Non-Cash Items | 42.51% | -255.02% | 34.84% | 85.75% | -256.99% |
| Change in Net Operating Assets | 4.24% | 15.25% | 13.77% | -35.46% | 15.54% |
| Cash from Operations | -3.90% | 22.68% | 8.29% | -35.71% | 35.57% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 49.45% | -164.66% | -1,308.06% | 84.49% | -341.16% |
| Cash from Investing | 49.45% | -164.66% | -1,308.06% | 84.49% | -341.16% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -74.20% | 30.74% | 40.50% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -4.83% | -4.80% | -4.79% | -5.84% | -6.10% |
| Other Financing Activities | 0.58% | -3.68% | -14.54% | 2.91% | 38.04% |
| Cash from Financing | -11.24% | 76.06% | 433.32% | -0.77% | 12.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 95.42% | 34.13% | 366.92% | 38.14% | -163.89% |
